Addison-Davis Diagnostics, Inc. Announces the Appointment of Stark-SMO

Westlake Village, California, UNITED STATES

WESTLAKE VILLAGE, Calif., Jan. 12, 2005 (PRIMEZONE) -- Addison-Davis Diagnostics, Inc. is pleased to announce the appointment of Stark-SMO, Inc. as ADDI's Site Management Organization. They will primarily be responsible for developing protocols for processing of ADDI's HIV 1 and 2 rapid-test product for final stage submission and clearance by the Federal Drug Administration.

Edward Withrow, CEO Addison-Davis Diagnostics, Inc says, "The addition of Stark-SMO to our team is a major step forward in our third-phase FDA clearance process for Addison-Davis's Target System HIV 1 & 2 Rapid Test. We at Addison-Davis believe that Stark-SMO possesses the experience necessary to manage and implement a successful third phase of our Target System HIV 1 & 2 FDA clearance process. We look forward to working with Stark-SMO on this extremely important project."

With more than 15 years of experience, Stark-SMO, Inc. conducts trials under strict adherence to FDA GCPs (Good Clinical Practices), and is dedicated to the highest levels of protocol compliance. The HIV 1 and 2 test utilizes ADDI's FDA 510(k)-cleared Target System Diagnostics platform for rapid-test diseases.

About Stark-SMO:

Stark-SMO is an innovative, comprehensive Site Management Organization that has experience in all phases of clinical trials. They specialize in employing proven training methods to cut down on adverse events and protocol deviations during the approval process. Stark-SMO applies its proven training and organization methods to all phases of clinical trials, with particular expertise in key disciplines; including Infectious Diseases, Cardiovascular studies, and Medical Devices. For more information about Stark-SMO, visit

About Addison-Davis:

Addison-Davis is currently focused on developing fast and reliable "Point-of-Care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, Minor Emergency Centers, Ambulance, Para-Medics and all branches of the Government. This innovative technology is suitable for the most common and time sensitive medical conditions and diseases. ADDI has licensed the patents to proven Point-of-Care quick-test devices and analyzers that easily evolve and adapt to the rapidly changing professional and governmental healthcare market. Many of these innovative devices are already Food and Drug Administration ("FDA") 510(k) cleared. For more information about Addison Davis Diagnostics, Inc visit:

To hear an audio interview with Edward Withrow, CEO of ADDI, please visit:

This press release contains forward-looking statements that involve risks, uncertainties and assumptions that if they never materialize or prove incorrect, could cause the results of Addison-Davis Diagnostics, Inc. to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations as of the date of this press release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in the reports filed by Addison-Davis Diagnostics, Inc. with the Securities and Exchange Commission. Addison-Davis Diagnostics, Inc. assumes no obligation and does not intend to update these forward-looking statements.


Contact Data